8th AVG Meeting
On behalf of the ISRV Antiviral Special Interest Group (AVG) we are excited to have our their 8th meeting, immediately preceding the IMRP in Singapore! After the COVID-19 pandemic, many are looking to leverage what we’ve learned to advance our approach to prevent and manage respiratory viral infections. We will start with a review of promising new drugs in clinical trials for influenza, RSV and COVID 19. There will be sessions to inform how to use various pre-clinical models and data to advance candidate antivirals into the clinic and then how to target the candidate therapeutic to the right patient, at the right time. We will then consider the role and regulatory hurdles of combination therapy or antivirals active against a range of viruses. We will explore the role of immune modulations in the care of patients with respiratory viral testing. The meeting will finish with two sessions focused on approaches to antivirals in pandemics and regulatory challenges in developing novel antivirals. This meeting will bring researchers, clinicians and regulators together to explore the challenges in antiviral development. It will also feature our 2nd Roberts/Tisdale Lectureship focused on the clinical implications of antiviral resistance.
